机构:[1]Department of Neurology, National Research Center for Aging and Medicine, National Center for Neurological Disorders, and State Key Laboratory of Medical Neurobiology, Huashan Hospital, Fudan University, Shanghai, China[2]Department of Nuclear Medicine & PET Center, National Center for Neurological Disorders, and National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China[3]APRINOIA Therapeutics Co Ltd, Suzhou, China[4]Department of Nuclear Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China[5]Department of Nuclear Medicine and PET/CT‑MRI Center, The First Affiliated Hospital of Jinan University, Guangzhou, China[6]Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属协和医院[7]Department of Nuclear Medicine, Xuanwu Hospital Capital Medical University, Beijing, China首都医科大学宣武医院[8]Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China[9]Department of Nuclear Medicine, University Hospital of Munich, LMU, Munich, Germany[10]DZNE – German Center for Neurodegenerative Diseases, Munich, Germany[11]Munich Cluster for Systems Neurology (SyNergy), Munich, Germany[12]Department of Nuclear Medicine, Inselspital, University of Bern, Bern, Switzerland[13]Department of Informatics, Technische Universitat Munchen, Munich, Germany[14]International Human Phenome Institutes (Shanghai), Shanghai, China[15]Human Phenome Institute, Fudan University, Shanghai, China
This work was funded by research grants from the National
Natural Science Foundation of China (82272039, 82021002,
82394430, 81971641, 82371266, 82171252, 82171421, 91949118,
82394434), the Science and Technology Innovation 2030 Major Project
(2022ZD0211600), the National Key R&D Program of China
(2022YFC2009902, 2022YFC2009900), the Shanghai Municipal
Science and Technology Major Project (2018SHZDZX01 and
21S31902200), the ZHANGJIANG LAB, the National Health Commission
of PRC (Pro20211231084249000238), the Research Project of the
Shanghai Health Commission (2020YJZX0111), the Medical Innovation
Research Project of the Shanghai Science and Technology Commission
(21Y11903300), the Deutsche Forschungsgemeinschaft (DFG) under
Germany’s Excellence Strategy within the framework of the Munich
Cluster for Systems Neurology (EXC 2145 SyNergy – ID 390857198).
第一作者机构:[1]Department of Neurology, National Research Center for Aging and Medicine, National Center for Neurological Disorders, and State Key Laboratory of Medical Neurobiology, Huashan Hospital, Fudan University, Shanghai, China
通讯作者:
通讯机构:[2]Department of Nuclear Medicine & PET Center, National Center for Neurological Disorders, and National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China[14]International Human Phenome Institutes (Shanghai), Shanghai, China[15]Human Phenome Institute, Fudan University, Shanghai, China
推荐引用方式(GB/T 7714):
Liu Feng-Tao,Lu Jia-Ying,Li Xin-Yi,et al.Visual reading for [18F]Florzolotau Tau PET scans in progressive supranuclear palsy[J].European Journal Of Nuclear Medicine And Molecular Imaging.2024,doi:10.1007/s00259-024-06923-3.
APA:
Liu Feng-Tao,Lu Jia-Ying,Li Xin-Yi,Ge Jing-Jie,Sun Yi-Min...&Zuo Chuan-Tao.(2024).Visual reading for [18F]Florzolotau Tau PET scans in progressive supranuclear palsy.European Journal Of Nuclear Medicine And Molecular Imaging,,
MLA:
Liu Feng-Tao,et al."Visual reading for [18F]Florzolotau Tau PET scans in progressive supranuclear palsy".European Journal Of Nuclear Medicine And Molecular Imaging .(2024)